GSK (GSK) Gross-Profit-to-Asset %

: 38.03% (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. GSK's annualized Gross Profit for the quarter that ended in Dec. 2023 was $28,527 Mil. GSK's average Total Assets over the quarter that ended in Dec. 2023 was $75,007 Mil. Therefore, GSK's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 38.03%.

GSK Gross-Profit-to-Asset % Historical Data

The historical data trend for GSK's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

32.25

20.77

20.61

26.99

37.24

GSK Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															35.37	33.68	36.25	38.68	38.03

Competitive Comparison

For the Drug Manufacturers - General subindustry, GSK's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GSK Gross-Profit-to-Asset % Distribution

For the Drug Manufacturers industry and Healthcare sector, GSK's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where GSK's Gross-Profit-to-Asset % falls into.

GSK Gross-Profit-to-Asset % Calculation

GSK's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	27548.101	/	( (73259.44	+	74689.873)	/ 2 )
	=	27548.101	/	73974.6565
	=	37.24 %

GSK's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	28526.584	/	( (75324.257	+	74689.873)	/ 2 )
	=	28526.584	/	75007.065
	=	38.03 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

GSK Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of GSK's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

GSK (GSK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (NYSE:GSK) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

GLAXF:USA GSK N:Mexico GSKl:UK GSK:UK GS71:Germany GS70:Germany GS71:Germany GS70:Germany GS71:Germany G1SK34:Brazil GSK:Argentina

Address

980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS

Website

https://www.gsk.com

In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.